Logo

PeptiDream Expands its Partnership with Novartis for Peptide Discovery

Share this
Novartis

PeptiDream Expands its Partnership with Novartis for Peptide Discovery

Shots:

  • PeptiDream has expanded its partnership with Novartis previously signed in 2019 for the discovery of peptides to be used as peptide-drug conjugate
  • The partnership will leverage PeptiDream’s Peptide Discovery Platform System (PDPS) technology to discover new macrocyclic peptides for Novartis-selected targets to be used in radionuclide conjugation and other therapeutic/diagnostic applications
  • Under the partnership, PeptiDream is entitled to receive $180M upfront, $2.71B development, regulatory & commercial milestones along with net-sales-based tiered royalties

Ref: PeptiDream | Image: Novartis

Related News:- PeptiDream Signs a Multi-Target Collaboration and License Agreement with Genentech to Discover and Develop Novel Peptide-Radioisotope Drug Conjugates

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions